FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316830058> ?p ?o ?g. }

• W2316830058 abstract "We conducted a multicentric randomized trial to compare bilateral orchiectomy versus bilateral orchiectomy plus etoposide or estramustine phosphate as first-line therapy for advanced prostatic cancer (stage D2).From January 1991 to December 1992 a total of 46 newly diagnosed cases (registered cases) of advanced (stage D2) prostatic cancer was randomized into 3 groups as follows; Group A: bilateral orchiectomy and 25 mg/day of etoposide every 2 weeks for 6 months. Group B: bilateral orchiectomy and 560 mg/day of estramustine phosphate for 6 months. Group C: bilateral orchiectomy alone. One of group A and one of group B were ineligible cases, so 44 were eligible. In the eligible cases, ages were ranged from 54 to 90 (mean of 71.2) years old. No significant difference of patients' characteristics was found among 3 groups and median follow-up period was 25 months. Response was evaluated based on the response criteria according to Japanese urological association. Specifically, a central pathologist who blinded to the treatment was employed for evaluating pathological response at six months.Of the 44 eligible patients, 33 and 25 were evaluated for clinically and pathological analyses, respectively. Clinical response rates were 80% (12/15) of group A, 100% (4/4) of group B and 78.6% (11/14) of group C. No significant difference in the clinical response and survival rate was shown among the three groups. Significantly higher frequencies of side effects were noted in the grop B compared to the other two groups (p < 0.05) and cardiovascular complications were the most frequent in group B. Favorable pathological response was obtained in all of group B, but not statistically significant compared with 7/21 (33.3%) of response rate in group A and C. The pathological response was significantly correlated with the clinical one in all patients (p < 0.01). While 8 of 11 patients (73%) with pathological response grade 1, 2 and 3 achieved clinical PR (partial response) or CR (complete response), only 5 of 14 (36%) with grade 0 received PR or CR.We conclude that low dose administration of etoposide or estramustine phosphate dose not improve clinical response and survival in a short term in castrated patients, but increases the adverse effects due to the drugs in these patients. In addition, the pathological evaluation at 6 months after treatment appears to reflect the clinical response at that time in newly diagnosed patients with advanced prostatic cancer." @default.
• W2316830058 created "2016-06-24" @default.
• W2316830058 creator A5010676211 @default.
• W2316830058 creator A5011250166 @default.
• W2316830058 creator A5012317846 @default.
• W2316830058 creator A5014480812 @default.
• W2316830058 creator A5014986743 @default.
• W2316830058 creator A5021006929 @default.
• W2316830058 creator A5041215411 @default.
• W2316830058 creator A5069478495 @default.
• W2316830058 creator A5074754481 @default.
• W2316830058 creator A5077550416 @default.
• W2316830058 date "1995-01-01" @default.
• W2316830058 modified "2023-10-17" @default.
• W2316830058 title "CLINICOPATHOLOGICAL EVALUATION OF ETOPOSIDE OR ESTRAMUSTINE PHOSPHATE IN CASTRATED PATIENTS WITH ADVANCED PROSTATIC CANCER" @default.
• W2316830058 cites W2007396556 @default.
• W2316830058 cites W2108955823 @default.
• W2316830058 cites W2120466617 @default.
• W2316830058 cites W2125923638 @default.
• W2316830058 cites W2400344578 @default.
• W2316830058 cites W2406638291 @default.
• W2316830058 cites W2733661610 @default.
• W2316830058 doi "https://doi.org/10.5980/jpnjurol1989.86.1530" @default.
• W2316830058 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7474602" @default.
• W2316830058 hasPublicationYear "1995" @default.
• W2316830058 type Work @default.
• W2316830058 sameAs 2316830058 @default.
• W2316830058 citedByCount "3" @default.
• W2316830058 crossrefType "journal-article" @default.
• W2316830058 hasAuthorship W2316830058A5010676211 @default.
• W2316830058 hasAuthorship W2316830058A5011250166 @default.
• W2316830058 hasAuthorship W2316830058A5012317846 @default.
• W2316830058 hasAuthorship W2316830058A5014480812 @default.
• W2316830058 hasAuthorship W2316830058A5014986743 @default.
• W2316830058 hasAuthorship W2316830058A5021006929 @default.
• W2316830058 hasAuthorship W2316830058A5041215411 @default.
• W2316830058 hasAuthorship W2316830058A5069478495 @default.
• W2316830058 hasAuthorship W2316830058A5074754481 @default.
• W2316830058 hasAuthorship W2316830058A5077550416 @default.
• W2316830058 hasBestOaLocation W23168300581 @default.
• W2316830058 hasConcept C121608353 @default.
• W2316830058 hasConcept C126322002 @default.
• W2316830058 hasConcept C126894567 @default.
• W2316830058 hasConcept C141071460 @default.
• W2316830058 hasConcept C146357865 @default.
• W2316830058 hasConcept C151730666 @default.
• W2316830058 hasConcept C168563851 @default.
• W2316830058 hasConcept C207886595 @default.
• W2316830058 hasConcept C2776694085 @default.
• W2316830058 hasConcept C2777785397 @default.
• W2316830058 hasConcept C2778119113 @default.
• W2316830058 hasConcept C2779256933 @default.
• W2316830058 hasConcept C2780192828 @default.
• W2316830058 hasConcept C2780201970 @default.
• W2316830058 hasConcept C2781440318 @default.
• W2316830058 hasConcept C2994223898 @default.
• W2316830058 hasConcept C71315377 @default.
• W2316830058 hasConcept C71924100 @default.
• W2316830058 hasConcept C86803240 @default.
• W2316830058 hasConceptScore W2316830058C121608353 @default.
• W2316830058 hasConceptScore W2316830058C126322002 @default.
• W2316830058 hasConceptScore W2316830058C126894567 @default.
• W2316830058 hasConceptScore W2316830058C141071460 @default.
• W2316830058 hasConceptScore W2316830058C146357865 @default.
• W2316830058 hasConceptScore W2316830058C151730666 @default.
• W2316830058 hasConceptScore W2316830058C168563851 @default.
• W2316830058 hasConceptScore W2316830058C207886595 @default.
• W2316830058 hasConceptScore W2316830058C2776694085 @default.
• W2316830058 hasConceptScore W2316830058C2777785397 @default.
• W2316830058 hasConceptScore W2316830058C2778119113 @default.
• W2316830058 hasConceptScore W2316830058C2779256933 @default.
• W2316830058 hasConceptScore W2316830058C2780192828 @default.
• W2316830058 hasConceptScore W2316830058C2780201970 @default.
• W2316830058 hasConceptScore W2316830058C2781440318 @default.
• W2316830058 hasConceptScore W2316830058C2994223898 @default.
• W2316830058 hasConceptScore W2316830058C71315377 @default.
• W2316830058 hasConceptScore W2316830058C71924100 @default.
• W2316830058 hasConceptScore W2316830058C86803240 @default.
• W2316830058 hasLocation W23168300581 @default.
• W2316830058 hasLocation W23168300582 @default.
• W2316830058 hasOpenAccess W2316830058 @default.
• W2316830058 hasPrimaryLocation W23168300581 @default.
• W2316830058 hasRelatedWork W1512232438 @default.
• W2316830058 hasRelatedWork W1970792195 @default.
• W2316830058 hasRelatedWork W2025323268 @default.
• W2316830058 hasRelatedWork W2080914660 @default.
• W2316830058 hasRelatedWork W2125923638 @default.
• W2316830058 hasRelatedWork W2316830058 @default.
• W2316830058 hasRelatedWork W2367301691 @default.
• W2316830058 hasRelatedWork W3009124764 @default.
• W2316830058 hasRelatedWork W3029929814 @default.
• W2316830058 hasRelatedWork W3032634864 @default.
• W2316830058 isParatext "false" @default.
• W2316830058 isRetracted "false" @default.
• W2316830058 magId "2316830058" @default.
• W2316830058 workType "article" @default.